Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q2 2021 · 10-Q
Revenue$68.00K$68.00K+58.1% vs Q2 2020 Net Income-$6.76M-$6.76MN/M vs Q2 2020 EPS Diluted-$0.17-$0.17N/M vs Q2 2020 Operating Income-$6,889,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$4,301,000N/M Margins · derivedOperating margin-10130.9%−591.3 pt vs Q2 2020
Net margin-9936.8%−346.1 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 5, 2021 · 36 d after period end